These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38512445)

  • 1. Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea.
    Kim H; Son N; Jeong D; Yoo M; Choi IY; Choi W; Chung YW; Ko SW; Byun S; Im S; Sim DW; Seo J; Kang MG; Lee JK; Seo YG; An HJ; Kim Y; Chae S; Jun DW; Chang DJ; Kim SG; Yi S; Yang HJ; Lee I; Park HJ; Lee JH; Kim B; Lee EE
    Drug Saf; 2024 Jul; 47(7):673-686. PubMed ID: 38512445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers.
    Choi WJ; Kim GA; Park J; Jang S; Jung WJ; Shim JJ; Park Y; Choi GH; Kim JW; Jeong SH; Jang ES
    J Korean Med Sci; 2022 Aug; 37(33):e255. PubMed ID: 35996932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer risk associated with the use of valsartan in Korea: A nationwide cohort study.
    Jeon HL; Lee SH; Nam JH; Shin JY
    Cancer Epidemiol; 2022 Oct; 80():102245. PubMed ID: 36087359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan and the risk of incident dementia in heart failure: a nationwide propensity-matched cohort study.
    Lee HJ; Kim HK; Kim BS; Han KD; Kwak S; Park CS; Rhee TM; Park JB; Lee H; Kim YJ
    Clin Res Cardiol; 2024 Jun; 113(6):875-883. PubMed ID: 37906294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort.
    Moon S; Lee HY; Jang J; Park SK
    J Prev Med Public Health; 2020 Dec; 53(6):476-486. PubMed ID: 33296588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
    Riaz M; Smith SM; Dietrich EA; Pepine CJ; Park H
    Pharmacotherapy; 2021 Sep; 41(9):710-721. PubMed ID: 34170559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance of Antihypertensive Medication and Risk of Coronavirus Disease 2019: a Cohort Study Using Big Data from the Korean National Health Insurance Service.
    Kim J; Kim DW; Kim KI; Kim HB; Kim JH; Lee YG; Byeon KH; Cheong HK;
    J Korean Med Sci; 2020 Jun; 35(25):e232. PubMed ID: 32597045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.
    Bhaskaran K; Douglas I; Evans S; van Staa T; Smeeth L
    BMJ; 2012 Apr; 344():e2697. PubMed ID: 22531797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal Detection of Potential Hepatotoxic Drugs: Case-Control Study Using Both a Spontaneous Reporting System and Electronic Medical Records.
    Akimoto H; Nagashima T; Minagawa K; Hayakawa T; Takahashi Y; Asai S
    Biol Pharm Bull; 2021; 44(10):1514-1523. PubMed ID: 34602560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study.
    Mansfield KE; Nitsch D; Smeeth L; Bhaskaran K; Tomlinson LA
    BMJ Open; 2016 Dec; 6(12):e012690. PubMed ID: 28003286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.
    Dudkowski C; Karim A; Zhao Z; Alonso AB; Garg D; Preston RA
    J Clin Pharmacol; 2018 Jan; 58(1):48-56. PubMed ID: 28750149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort.
    Lu Y; Van Zandt M; Liu Y; Li J; Wang X; Chen Y; Chen Z; Cho J; Dorajoo SR; Feng M; Hsu MH; Hsu JC; Iqbal U; Jonnagaddala J; Li YC; Liaw ST; Lim HS; Ngiam KY; Nguyen PA; Park RW; Pratt N; Reich C; Rhee SY; Sathappan SMK; Shin SJ; Tan HX; You SC; Zhang X; Krumholz HM; Suchard MA; Xu H
    JAMA Netw Open; 2022 Mar; 5(3):e223877. PubMed ID: 35323951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Verification of Time-Series Deep Learning for Drug-Induced Liver Injury Detection in Patients Taking Angiotensin II Receptor Blockers: A Multicenter Distributed Research Network Approach.
    Heo S; Yu JY; Kang EA; Shin H; Ryu K; Kim C; Chegal Y; Jung H; Lee S; Park RW; Kim K; Hwangbo Y; Lee JH; Park YR
    Healthc Inform Res; 2023 Jul; 29(3):246-255. PubMed ID: 37591680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension.
    Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H
    Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
    Haroon S; Subramanian A; Cooper J; Anand A; Gokhale K; Byne N; Dhalla S; Acosta-Mena D; Taverner T; Okoth K; Wang J; Chandan JS; Sainsbury C; Zemedikun DT; Thomas GN; Parekh D; Marshall T; Sapey E; Adderley NJ; Nirantharakumar K
    BMC Infect Dis; 2021 Mar; 21(1):262. PubMed ID: 33722197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.